Management of Acute Myeloid Leukemia in Older Adults

1. Initial Assessment & Molecular Testing

Fitness for intensive therapy is determined by performance status, cardiac function, renal function (creatinine > 1.3 mg/dL indicates unfitness), and comorbidities rather than chronological age. National Comprehensive Cancer Network (NCCN) recommendation. [@1]
Mandatory baseline molecular testing includes FLT3‑ITD/TKD, IDH1/2, NPM1, and TP53 because results direct targeted‑agent selection. NCCN. [@1]
IDH1/2‑mutated disease predicts a 71‑72 % complete remission (CR/CRi) rate to venetoclax‑based regimens. NCCN. [@1]
NPM1‑mutated AML achieves an 89 % CR/CRi rate when venetoclax is combined with low‑dose cytarabine. NCCN. [@1]
TP53‑mutated AML shows poor outcomes, with only 30‑47 % CR/CRi even with venetoclax‑hypomethylating agent (HMA) combinations. NCCN. [@1]
Cytogenetic risk stratification (favorable, intermediate, adverse) predicts expected remission rates and guides consolidation intensity. American Society of Hematology (ASH). [@5]

In fit patients (good performance status, limited comorbidities), intensive chemotherapy provides superior quality of life and overall survival compared with supportive care alone. ASH. [@5]

Clinical Scenario	Preferred Regimen	Key Outcome
Therapy‑related AML or AML with myelodysplasia‑related changes	CPX‑351 (liposomal daunorubicin 44 mg/m² + cytarabine 100 mg/m² on days 1, 3, 5)	2‑year OS 31.1 % vs 12.3 % with standard 7+3
FLT3‑ITD/TKD‑positive (any allelic ratio)	Standard 7+3 + midostaurin 50 mg BID days 8‑21	4‑year OS 51.4 %
Core‑binding factor AML with ≥30 % CD33‑positive blasts	7+3 + gemtuzumab ozogamicin (GO) 3 mg/m² day 1	6‑year OS 75.5 % (increase of 20.7 % vs 7+3 alone)
CBF‑AML in patients ≥66 y	7+3 (as above)	CR ≈ 75 %; early death ≈ 16 %
Cytogenetically normal AML with NPM1 mutation (± FLT3‑ITD)	Standard 7+3 (consider dose‑escalated cytarabine consolidation)	Improved remission durability
No specific molecular/ cytogenetic feature	Standard 7+3 remains backbone	Established efficacy

All regimens above are endorsed by the *National Comprehensive Cancer Network (NCCN)*. [@8]

Favorable‑risk genetics (e.g., CBF‑AML, NPM1‑mutated without FLT3‑ITD): 2‑4 cycles of intermediate‑dose cytarabine (1‑1.5 g/m² q12 h × 6 doses). ASH. [@5]
Intermediate‑risk genetics: Allogeneic stem‑cell transplantation in first remission if a suitable donor is available. ASH. [@5]
Adverse‑risk genetics: Proceed directly to allogeneic transplantation when medically feasible. ASH. [@5]

Patients ≥75 y, or those with ECOG ≥ 2, significant cardiac dysfunction, or renal impairment, should receive lower‑intensity regimens. NCCN. [@1]

Venetoclax 400 mg daily (after ramp‑up) + azacitidine 75 mg/m² days 1‑7 or decitabine 20 mg/m² days 1‑5 (FDA‑approved, NCCN Category 1). Outcomes: CR/CRi ≈ 67 %; median OS ≈ 17.5 months; median remission duration ≈ 11.3 months. NCCN. [@1]

Mutation / Cytogenetic Risk	CR/CRi Rate	Median Remission Duration
IDH1/2 mutation	71‑72 %	8.1‑11.3 months
NPM1 mutation	89 %	Not reached
FLT3 mutation	44‑72 %	Variable
TP53 mutation	30‑47 %	6.7 months
Intermediate‑risk cytogenetics	74 %	12.9 months
Adverse‑risk cytogenetics	60 %	6.7 months
De novo AML	67‑71 %	9.4‑11.3 months
Secondary AML	67 %	Not reached

Data derived from NCCN guidelines.

IDH1‑mutated AML: Ivosidenib 500 mg daily → CR/CRh ≈ 41.2 %; overall response ≈ 58.8 %. NCCN. [@3]
IDH2‑mutated AML: Enasidenib 100 mg daily (monotherapy). NCCN. [@3]
FLT3‑mutated AML: Azacitidine + gilteritinib → CR/CRi ≈ 67 % (preliminary). NCCN. [@3]
No actionable mutation: Azacitidine or decitabine monotherapy (fallback). Azacitidine improves median OS to 10.4 months vs 6.5 months with conventional care; decitabine yields CR ≈ 18 % and median OS ≈ 7.7 months. NCCN. [@1][@4][@10]

Venetoclax 600 mg + low‑dose cytarabine (LDAC) → CR/CRi ≈ 54 %; median OS ≈ 10.1 months (inferior to venetoclax‑HMA). NCCN. [@1]
Glasdegib 100 mg + LDAC → median OS ≈ 8.8 months vs 4.9 months with LDAC alone; CR ≈ 17 %. NCCN. [@1]
LDAC monotherapy → CR ≈ 18 %; 30‑day mortality ≈ 26 %; no benefit in adverse‑risk cytogenetics. NCCN. [@1]

Continue venetoclax‑HMA until disease progression or unacceptable toxicity. NCCN. [@2]
Assess response after 1‑2 cycles; if no improvement after 4 cycles, switch to an alternative regimen or clinical trial. NCCN. [@2]
Induction mortality with lower‑intensity regimens ranges from 7‑26 %; careful patient selection is essential. NCCN. [@1]

Lower‑intensity responders: Maintain venetoclax‑HMA indefinitely until progression. NCCN. [@2]
Allogeneic transplantation: Offer reduced‑intensity conditioning to eligible responders for potential cure. ASH. [@5][@9]
Intensive‑therapy responders:
- Favorable‑risk: 2‑4 cycles intermediate‑dose cytarabine consolidation. ASH. [@5]
- Intermediate/Adverse‑risk: Proceed to allogeneic transplantation if feasible. ASH. [@5]

For patients declining or unfit for antileukemic therapy, hydroxyurea to maintain white‑blood‑cell count <10 × 10⁹/L plus transfusion support is appropriate. NCCN. [@1]
LDAC provides only modest survival benefit over hydroxyurea (median OS difference < 3 months) and carries a 26 % 30‑day mortality. ASH. [@5]

Do not use LDAC monotherapy in adverse‑risk cytogenetics—offers no benefit and incurs high early mortality. NCCN. [@1]
Do not delay FLT3, IDH1/2, NPM1, or TP53 testing; results fundamentally alter treatment choice. NCCN. [@1]
Do not continue ineffective therapy beyond 4 cycles; reassess and consider alternative strategies. NCCN. [@2]
Do not withhold intensive therapy solely based on age; fitness assessment determines eligibility. ASH. [@5]
Avoid gemtuzumab ozogamicin in adverse‑risk cytogenetics—no overall‑survival benefit and increased toxicity. NCCN. [@1]
Ensure a minimum 2‑month interval between the last GO dose and conditioning for allogeneic transplantation to reduce hepatic sinusoidal obstruction syndrome risk. NCCN. [@8]